Technical Momentum and Price Action
On 30 Sep 2026, Venus Remedies closed at ₹1,710.90, marking a notable 4.92% gain from the previous close of ₹1,630.70. The intraday range was relatively tight, with a low of ₹1,625.80 and a high of ₹1,712.20, indicating strong buying interest near the upper band. The stock remains comfortably above its 52-week low of ₹423.70 and is inching closer to its 52-week high of ₹2,043.15, signalling a sustained uptrend over the past year.
The daily moving averages have turned bullish, reinforcing the positive price momentum. This is a critical development as moving averages often act as dynamic support and resistance levels, and their bullish alignment suggests that the stock is likely to maintain its upward trajectory in the near term.
MACD and RSI Analysis
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD remains mildly bearish, reflecting some short-term consolidation or profit-taking. However, the monthly MACD is bullish, indicating that the longer-term momentum is firmly positive. This divergence suggests that while short-term fluctuations may occur, the broader trend favours buyers.
Relative Strength Index (RSI) readings on both weekly and monthly charts currently show no definitive signal, hovering in neutral zones. This implies that the stock is neither overbought nor oversold, providing room for further upward movement without immediate risk of a sharp correction.
Bollinger Bands and KST Indicator
Bollinger Bands have turned bullish on both weekly and monthly timeframes, signalling increased volatility accompanied by upward price pressure. The stock price is trading near the upper band, which often acts as a resistance level but also confirms strong buying momentum when breached.
The Know Sure Thing (KST) indicator, a momentum oscillator, shows a mildly bearish stance on the weekly chart but a bullish trend on the monthly chart. This mixed signal aligns with the MACD readings and suggests that short-term traders should exercise caution, while long-term investors can remain optimistic.
Volume and Dow Theory Insights
On-Balance Volume (OBV) does not currently indicate a clear trend on either weekly or monthly charts, suggesting that volume has not decisively confirmed the price moves. However, the Dow Theory assessment is mildly bullish on the weekly timeframe, indicating that the stock is in a phase of accumulation or early-stage uptrend. The monthly Dow Theory shows no clear trend, reinforcing the need for investors to monitor developments closely.
Comparative Performance Against Sensex
Venus Remedies has delivered exceptional returns relative to the benchmark Sensex over multiple time horizons. Year-to-date, the stock has surged by 123.06%, while the Sensex declined by 14.89%. Over the past year, Venus Remedies soared 296.64%, contrasting sharply with the Sensex’s 9.75% decline. Even over longer periods such as three, five, and ten years, the stock’s returns of 576.65%, 278.81%, and an extraordinary 1,524.02% respectively, dwarf the Sensex’s gains of 10.18%, 22.08%, and 160.64%.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Mojo Score Upgrade and Market Capitalisation
Venus Remedies’ Mojo Score has improved to 74.0, earning a Buy grade as of 29 Sep 2026, upgraded from a previous Hold rating. This upgrade reflects the company’s strengthening fundamentals and technical outlook. Despite being classified as a micro-cap stock, the company’s robust price action and technical indicators suggest it is gaining traction among investors seeking growth opportunities in the Pharmaceuticals & Biotechnology sector.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies benefits from sector tailwinds such as increased healthcare spending, innovation in drug development, and rising demand for pharmaceutical products. The sector’s inherent volatility often rewards companies demonstrating strong technical momentum and solid fundamentals, positioning Venus Remedies favourably for continued gains.
Technical Summary and Outlook
The overall technical trend for Venus Remedies has shifted from mildly bullish to bullish, supported by daily moving averages and monthly momentum indicators. While some weekly indicators like MACD and KST show mild bearishness, these are likely short-term pauses within a broader uptrend. The neutral RSI readings suggest the stock is not overextended, allowing room for further appreciation.
Investors should monitor the stock’s ability to sustain above key moving averages and watch for confirmation from volume-based indicators such as OBV. A breakout above the 52-week high of ₹2,043.15 could signal a new leg higher, while any sustained dip below daily moving averages might warrant caution.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Investor Considerations
Given the stock’s strong relative performance and technical upgrade, investors with a medium to long-term horizon may find Venus Remedies an attractive addition to their portfolios. The stock’s micro-cap status entails higher volatility and risk, but the current technical signals and sector dynamics provide a compelling case for upside potential.
Risk-averse investors should remain vigilant for any signs of weakening momentum, particularly if weekly MACD and KST indicators deteriorate further or if the stock fails to hold above key moving averages. Diversification and position sizing remain essential when engaging with micro-cap stocks in the volatile pharmaceutical space.
Conclusion
Venus Remedies Ltd’s recent technical parameter changes highlight a clear shift towards bullish momentum, supported by strong moving averages, positive monthly MACD, and bullish Bollinger Bands. The stock’s impressive outperformance relative to the Sensex over multiple timeframes underscores its growth credentials. With a Mojo Score upgrade to Buy and a micro-cap valuation, Venus Remedies is poised for further gains, provided it maintains its technical strength and navigates sector challenges effectively.
Investors should continue to monitor technical indicators closely, balancing the promising long-term outlook against short-term fluctuations. Overall, Venus Remedies presents a compelling opportunity for those seeking exposure to the Pharmaceuticals & Biotechnology sector with a focus on technical momentum and growth potential.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
